Monthly update of U.S. Food and Drug Administration (FDA) approvals impacting the workers' compensation industry. myMatrixx's report includes new drug and indication approvals, discontinuation and withdrawals, new dosages or formulations of existing products and newly available generics in the last 12 months.
Monthly Drug News
A generic version of Boehringer Ingelheim’s Pradaxa® (dabigatran oral tablets) is now available, although only for the lower 75 mg strength. Pradaxa is an anticoagulant medication often used for treatment or prophylaxis of various blood clots. It is frequently utilized in certain cardiac conditions or following surgery.
Impact to Workers’ Comp
This is not as impactful as it will be when other anticoagulants become available as generics. The fact that it is only the 75 mg strength will further limit that. For any questions about the use of Pradaxa, anticoagulants, and potential relatedness to a claim, please consult with your myMatrixx pharmacist.